Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | pantoate-beta-alanine ligase | 0.0627 | 0.3785 | 0.5 |
Onchocerca volvulus | 0.0047 | 0 | 0.5 | |
Echinococcus granulosus | survival motor neuron protein 1 | 0.0232 | 0.1206 | 0.5 |
Schistosoma mansoni | survival motor neuron protein | 0.0047 | 0 | 0.5 |
Mycobacterium tuberculosis | Pantoate--beta-alanine ligase PanC (pantothenate synthetase) (pantoate activating enzyme) | 0.0627 | 0.3785 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0047 | 0 | 0.5 |
Mycobacterium ulcerans | pantoate--beta-alanine ligase | 0.0627 | 0.3785 | 0.5 |
Mycobacterium leprae | Probable pantoate--beta-alanine ligase PanC (pantothenate synthetase) (pantoate activating enzyme) | 0.0627 | 0.3785 | 0.5 |
Brugia malayi | hypothetical protein | 0.0232 | 0.1206 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0232 | 0.1206 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.